 This entry in the Crime Does Not Pay series focuses on the U.S. Food and Drug Administration s effort to ensure that drugs are fully tested before they are sold to consumers. Two unscrupulous investors market the drug  Diabulin  as a substitute for insulin after preliminary tests show good results. After a short time, however, users start dying from the drug. The FDA and the state attorney general s office then go after the drug marketers.